AngioDynamics Inc (ANGO) · Insider trading
What AngioDynamics's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$118,100
1 insider, 1 trade
Sold, 12 months
$344,006
1 insider, 0% under a plan
Net, 12 months
−$225,906
bought less sold
Latest filing
2026-07-31
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Nighan Warren JrSVP Quality and Regulatory | – | $393,985 | 2 | 2026-07-30 | 64,745 |
| Weiss Lawrence TSVP, Chief Legal Officer | $118,100 | – | 1 | 2025-10-21 | 93,597 |
| Clemmer James CDirector, President and CEO | $111,500 | – | 1 | 2025-10-09 | 882,529 |
| Trowbridge Stephen AEVP and CFO | $9,932 | – | 1 | 2025-10-13 | 256,629 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-30 | Nighan Warren JrSVP Quality and Regulatory | Sale | 23,370 | 14.72 | $344,006 | 64,745 | Form 4 |
| 2025-10-21 | Weiss Lawrence TSVP, Chief Legal Officer | Buy | 10,000 | 11.81 | $118,100 | 93,597 | Form 4 |
| 2025-10-13 | Trowbridge Stephen AEVP and CFO | Buy | 890 | 11.16 | $9,932 | 256,629 | Form 4 |
| 2025-10-09 | Clemmer James CDirector, President and CEO | Buy | 10,000 | 11.15 | $111,500 | 882,529 | Form 4 |
| 2025-01-16 | Nighan Warren JrSVP Quality and Regulatory | Sale | 4,060 | 12.31 | $49,979 | 41,817 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
39 × shares withheld for tax26 × grant or award5 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-22 | Campbell Chad ThomasSVP/GM, Vascular Access | Option exercise M | +6,466 | – | 111,006 | Form 4 |
| 2026-07-22 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax F | −2,330 | 13.82 | 108,676 | Form 4 |
| 2026-07-22 | Clemmer James CDirector, President and CEO | Option exercise M | +52,358 | – | 889,176 | Form 4 |
| 2026-07-22 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −26,728 | 13.82 | 862,448 | Form 4 |
| 2026-07-22 | Trowbridge Stephen AEVP and CFO | Option exercise M | +16,296 | – | 314,115 | Form 4 |
| 2026-07-22 | Trowbridge Stephen AEVP and CFO | Shares withheld for tax F | −8,319 | 13.82 | 305,796 | Form 4 |
| 2026-07-22 | Nighan Warren JrSVP Quality and Regulatory | Option exercise M | +5,694 | – | 89,786 | Form 4 |
| 2026-07-22 | Nighan Warren JrSVP Quality and Regulatory | Shares withheld for tax F | −1,671 | 13.82 | 88,115 | Form 4 |
| 2026-07-22 | Piccinini LauraSVP International | Option exercise M | +8,047 | – | 86,435 | Form 4 |
| 2026-07-22 | Piccinini LauraSVP International | Shares withheld for tax F | −4,506 | 13.82 | 81,929 | Form 4 |
| 2026-07-20 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax F | −359 | 13.71 | 88,459 | Form 4 |
| 2026-07-20 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −4,223 | 13.71 | 836,818 | Form 4 |
| 2026-07-20 | Nighan Warren JrSVP Quality and Regulatory | Shares withheld for tax F | −251 | 13.71 | 66,126 | Form 4 |
| 2026-07-20 | Piccinini LauraSVP International | Shares withheld for tax F | −616 | 13.71 | 58,528 | Form 4 |
| 2026-07-20 | Trowbridge Stephen AEVP and CFO | Shares withheld for tax F | −717 | 13.71 | 244,562 | Form 4 |
| 2026-07-19 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −11,764 | 13.51 | 841,528 | Form 4 |
| 2026-07-19 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −487 | 13.51 | 841,041 | Form 4 |
| 2026-07-17 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax F | −1,112 | 13.51 | 88,818 | Form 4 |
| 2026-07-17 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −10,649 | 13.51 | 853,292 | Form 4 |
| 2026-07-17 | Nighan Warren JrSVP Quality and Regulatory | Shares withheld for tax F | −1,373 | 13.51 | 66,377 | Form 4 |
| 2026-07-17 | Piccinini LauraSVP International | Shares withheld for tax F | −3,074 | 13.51 | 59,144 | Form 4 |
| 2026-07-17 | Trowbridge Stephen AEVP and CFO | Shares withheld for tax F | −3,510 | 13.51 | 245,279 | Form 4 |
| 2026-07-16 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax F | −2,367 | 14.14 | 89,930 | Form 4 |
| 2026-07-16 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −18,588 | 14.14 | 863,941 | Form 4 |
| 2026-07-16 | Nighan Warren JrSVP Quality and Regulatory | Shares withheld for tax F | −2,153 | 14.14 | 67,750 | Form 4 |
| 2026-07-16 | Piccinini LauraSVP International | Shares withheld for tax F | −4,538 | 14.14 | 62,218 | Form 4 |
| 2026-07-16 | Trowbridge Stephen AEVP and CFO | Shares withheld for tax F | −7,840 | 14.14 | 248,789 | Form 4 |
| 2026-07-16 | Weiss Lawrence TSVP, Chief Legal Officer | Shares withheld for tax F | −2,267 | 14.14 | 91,330 | Form 4 |
| 2026-07-15 | Weiss Lawrence TSVP, Chief Legal Officer | Grant or award A | +21,288 | – | 112,618 | Form 4 |
| 2026-07-15 | Campbell Chad ThomasSVP/GM, Vascular Access | Grant or award A | +16,081 | – | 104,540 | Form 4 |
| 2026-07-15 | Nighan Warren JrSVP Quality and Regulatory | Grant or award A | +17,966 | – | 84,092 | Form 4 |
| 2026-07-15 | Piccinini LauraSVP International | Grant or award A | +19,860 | – | 78,388 | Form 4 |
| 2026-07-15 | Trowbridge Stephen AEVP and CFO | Grant or award A | +53,257 | – | 297,819 | Form 4 |
| 2026-07-15 | Tarnoff Michael EDirector | Grant or award A | +11,887 | – | 95,265 | Form 4 |
| 2026-07-15 | Auen Eileen O'SheaDirector | Grant or award A | +11,887 | – | 116,605 | Form 4 |
| 2026-07-15 | Burgess LorindaDirector | Grant or award A | +11,887 | – | 67,144 | Form 4 |
| 2026-07-15 | Donnelly Howard WDirector | Grant or award A | +11,887 | – | 178,938 | Form 4 |
| 2026-07-15 | Johnson WesleyDirector | Grant or award A | +11,887 | – | 155,425 | Form 4 |
| 2026-07-15 | Licitra Karen ADirector | Grant or award A | +11,887 | – | 102,322 | Form 4 |
| 2026-07-15 | Reed Jan SternDirector | Grant or award A | +11,887 | – | 116,921 | Form 4 |
| 2025-07-21 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax F | −395 | 8.99 | 92,297 | Form 4 |
| 2025-07-21 | Nighan Warren JrSVP Quality and Regulatory | Shares withheld for tax F | −277 | 8.99 | 69,903 | Form 4 |
| 2025-07-21 | Trowbridge Stephen AEVP and CFO | Shares withheld for tax F | −667 | 8.99 | 255,739 | Form 4 |
| 2025-07-20 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax F | −359 | 8.69 | 92,692 | Form 4 |
| 2025-07-20 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −2,982 | 8.69 | 876,202 | Form 4 |
| 2025-07-20 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −3,673 | 8.99 | 872,529 | Form 4 |
| 2025-07-20 | Nighan Warren JrSVP Quality and Regulatory | Shares withheld for tax F | −251 | 8.69 | 70,180 | Form 4 |
| 2025-07-20 | Piccinini LauraSVP International | Shares withheld for tax F | −616 | 8.69 | 66,756 | Form 4 |
| 2025-07-20 | Trowbridge Stephen AEVP and CFO | Shares withheld for tax F | −717 | 8.69 | 256,406 | Form 4 |
| 2025-07-19 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax F | −1,025 | 8.69 | 93,051 | Form 4 |
| 2025-07-19 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −344 | 8.69 | 887,491 | Form 4 |
| 2025-07-19 | Clemmer James CDirector, President and CEO | Shares withheld for tax F | −8,307 | 8.69 | 879,184 | Form 4 |
| 2025-07-19 | Nighan Warren JrSVP Quality and Regulatory | Shares withheld for tax F | −735 | 8.69 | 70,431 | Form 4 |
| 2025-07-19 | Piccinini LauraSVP International | Shares withheld for tax F | −1,983 | 8.69 | 67,372 | Form 4 |
| 2025-07-19 | Trowbridge Stephen AEVP and CFO | Shares withheld for tax F | −2,585 | 8.69 | 257,123 | Form 4 |
| 2025-07-17 | Piccinini LauraSVP International | Shares withheld for tax F | −3,074 | 8.74 | 69,355 | Form 4 |
| 2025-07-16 | Johnson WesleyDirector | Grant or award A | +17,675 | – | 143,538 | Form 4 |
| 2025-07-16 | Licitra Karen ADirector | Grant or award A | +17,675 | – | 90,435 | Form 4 |
| 2025-07-16 | Reed Jan SternDirector | Grant or award A | +17,675 | – | 105,034 | Form 4 |
| 2025-07-16 | Tarnoff Michael EDirector | Grant or award A | +17,675 | – | 83,378 | Form 4 |
| 2025-07-16 | Auen Eileen O'SheaDirector | Grant or award A | +17,675 | – | 104,718 | Form 4 |
| 2025-07-16 | Burgess LorindaDirector | Grant or award A | +17,675 | – | 55,257 | Form 4 |
| 2025-07-16 | Donnelly Howard WDirector | Grant or award A | +17,675 | – | 167,051 | Form 4 |
| 2025-07-16 | Campbell Chad ThomasSVP/GM, Vascular Access | Grant or award A | +26,268 | – | 94,076 | Form 4 |
| 2025-07-16 | Trowbridge Stephen AEVP and CFO | Grant or award A | +86,997 | – | 259,708 | Form 4 |
| 2025-07-16 | Weiss Lawrence TSVP, Chief Legal Officer | Grant or award A | +30,900 | – | 83,597 | Form 4 |
| 2025-07-16 | Clemmer James CDirector, President and CEO | Grant or award A | +206,253 | – | 887,835 | Form 4 |
| 2025-07-16 | Nighan Warren JrSVP Quality and Regulatory | Grant or award A | +29,349 | – | 71,166 | Form 4 |
| 2025-07-16 | Piccinini LauraSVP International | Grant or award A | +32,423 | – | 72,429 | Form 4 |
| 2024-12-02 | Weiss Lawrence TSVP, Chief Legal Officer | Grant or award A | +52,697 | – | 52,697 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.